Royalty Pharma plc Gain (Loss) on Derivative Instruments, Net, Pretax
Royalty Pharma plc (RPRX) reported Gain (Loss) on Derivative Instruments, Net, Pretax of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDerivativeInstrumentsNetPretax · last filed 2026-02-11
- Royalty Pharma plc gain (loss) on derivative instruments, net, pretax for the quarter ending 2025-12-31 was -$1.00M.
- Royalty Pharma plc gain (loss) on derivative instruments, net, pretax for the quarter ending 2025-09-30 was $4.00M, a 33.33% increase year-over-year.
- Royalty Pharma plc gain (loss) on derivative instruments, net, pretax for the quarter ending 2025-06-30 was -$2.00M.
- Royalty Pharma plc gain (loss) on derivative instruments, net, pretax for the quarter ending 2025-03-31 was -$1.00M.
- Royalty Pharma plc gain (loss) on derivative instruments, net, pretax for fiscal 2025 was $0.00.
- Royalty Pharma plc gain (loss) on derivative instruments, net, pretax for fiscal 2024 was -$6.00M.
- Royalty Pharma plc gain (loss) on derivative instruments, net, pretax for fiscal 2023 was -$2.29M, a 102.37% decline from fiscal 2022.
- Royalty Pharma plc gain (loss) on derivative instruments, net, pretax for fiscal 2022 was $96.61M.
| Period end | Gain (Loss) on Derivative Instruments, Net, Pretax 3 month | Gain (Loss) on Derivative Instruments, Net, Pretax 6 month | Gain (Loss) on Derivative Instruments, Net, Pretax 9 month | Gain (Loss) on Derivative Instruments, Net, Pretax 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $3.00M derived: sum of 2 quarters · filed 2026-02-11 | $1.00M derived: sum of 3 quarters · filed 2026-02-11 | $0.00 10-K · filed 2026-02-11 |
| 2025-09-30 | $4.00M 10-Q · filed 2025-11-05 | $2.00M derived: sum of 2 quarters · filed 2025-11-05 | $1.00M 10-Q · filed 2025-11-05 | -$8.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-06-30 | -$2.00M 10-Q · filed 2025-08-06 | -$3.00M 10-Q · filed 2025-08-06 | -$12.00M derived: sum of 3 quarters · filed 2026-02-11 | -$9.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-03-31 | -$1.00M 10-Q · filed 2025-05-08 | -$10.00M derived: sum of 2 quarters · filed 2026-02-11 | -$7.00M derived: sum of 3 quarters · filed 2026-02-11 | -$7.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-12-31 | -$9.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$6.00M derived: sum of 2 quarters · filed 2026-02-11 | -$6.00M derived: sum of 3 quarters · filed 2026-02-11 | -$6.00M 10-K · filed 2026-02-11 |
| 2024-09-30 | $3.00M 10-Q · filed 2025-11-05 | $3.00M derived: sum of 2 quarters · filed 2025-11-05 | $3.00M 10-Q · filed 2025-11-05 | $3.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | -$8.68M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | -$8.68M derived: sum of 3 quarters · filed 2026-02-11 | -$9.38M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$8.68M derived: sum of 2 quarters · filed 2026-02-11 | -$9.38M derived: sum of 3 quarters · filed 2026-02-11 | -$2.29M 10-K · filed 2026-02-11 |
| 2023-09-30 | -$8.68M 10-Q · filed 2024-11-06 | -$9.38M derived: sum of 2 quarters · filed 2024-11-06 | -$2.29M 10-Q · filed 2024-11-06 | -$3.27M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | -$700.00K 10-Q · filed 2024-08-08 | $6.39M 10-Q · filed 2024-08-08 | $5.41M derived: sum of 3 quarters · filed 2025-02-12 | $31.20M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $7.09M 10-Q · filed 2024-05-09 | $6.11M derived: sum of 2 quarters · filed 2025-02-12 | $31.89M derived: sum of 3 quarters · filed 2025-02-12 | $103.70M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | -$980.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $24.80M derived: sum of 2 quarters · filed 2025-02-12 | $96.61M derived: sum of 3 quarters · filed 2025-02-12 | $96.61M 10-K · filed 2025-02-12 |
| 2022-09-30 | $25.79M 10-Q · filed 2023-11-08 | $97.59M derived: sum of 2 quarters · filed 2023-11-08 | $97.59M 10-Q · filed 2023-11-08 | $97.49M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $71.81M 10-Q · filed 2023-08-08 | $71.81M 10-Q · filed 2023-08-08 | $71.71M derived: sum of 3 quarters · filed 2024-02-15 | $54.74M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | -$96.00K derived: sum of 2 quarters · filed 2024-02-15 | -$17.07M derived: sum of 3 quarters · filed 2024-02-15 | -$18.98M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$96.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$17.07M derived: sum of 2 quarters · filed 2024-02-15 | -$18.98M derived: sum of 3 quarters · filed 2024-02-15 | -$21.53M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$16.97M 10-Q · filed 2022-11-08 | -$18.88M derived: sum of 2 quarters · filed 2022-11-08 | -$21.44M 10-Q · filed 2022-11-08 | -$23.63M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | -$1.91M 10-Q · filed 2022-08-04 | -$4.46M 10-Q · filed 2022-08-04 | -$6.65M derived: sum of 3 quarters · filed 2023-02-15 | -$13.74M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | -$2.56M 10-Q · filed 2022-05-05 | -$4.75M derived: sum of 2 quarters · filed 2023-02-15 | -$11.83M derived: sum of 3 quarters · filed 2023-02-15 | -$11.19M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | -$2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | -$9.28M derived: sum of 2 quarters · filed 2023-02-15 | -$8.63M derived: sum of 3 quarters · filed 2023-02-15 | -$42.08M 10-K · filed 2023-02-15 |
| 2020-09-30 | -$7.09M 10-Q · filed 2021-11-10 | -$6.44M derived: sum of 2 quarters · filed 2021-11-10 | -$39.89M 10-Q · filed 2021-11-10 | -$248.00K derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $647.00K 10-Q · filed 2021-08-11 | -$32.80M 10-Q · filed 2021-08-11 | $6.84M derived: sum of 3 quarters · filed 2022-02-15 | -$6.68M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | -$33.45M 10-Q · filed 2021-05-11 | $6.19M derived: sum of 2 quarters · filed 2022-02-15 | -$7.33M derived: sum of 3 quarters · filed 2022-02-15 | -$46.74M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $39.64M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $26.12M derived: sum of 2 quarters · filed 2022-02-15 | -$13.30M derived: sum of 3 quarters · filed 2022-02-15 | -$39.14M 10-K · filed 2022-02-15 |
| 2019-09-30 | -$13.52M 10-Q · filed 2020-11-12 | -$52.94M derived: sum of 2 quarters · filed 2020-11-12 | -$78.78M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$39.41M 10-Q · filed 2020-08-12 | -$65.25M 10-Q · filed 2020-08-12 | ||
| 2018-12-31 | $11.92M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |